Importantly, treatment with BEVs‐LCTP‐siSLC7A11 not only impaired tumorigenesis but also activated ferroptosis pathways, as evidenced by altered expression levels of SLC7A11 and transferrin in tumor and metastatic tissues. The gene discussed is SLC7A11; the disease is neoplasm.